Editorial: Data-driven clinical biosignatures and treatment for neurodegenerative diseases, volume II

The pursuit of reliable, effective, and convenient biosignatures is paramount for the early diagnosis of neurodegenerative diseases (NDD), offering crucial insights into optimal treatment timing and disease progression (Wang et al., 2023). Recent advancements have led to the discovery of novel biosignatures and treatment modalities for NDD. For instance, Zetterberg's team identified a plasma p-tau217 immunoassay that accurately detects Alzheimer's Disease (AD), comparable to cerebrospinal fluid (CSF) biomarkers (Ashton et al., 2024). Similarly, Hansson et al. demonstrated the clinical efficacy of blood plasma p-tau217 for AD pathology detection, surpassing FDA-approved CSF tests (Barthélemy et al., 2024). Additionally, studies underscore the role of metabolic waste accumulation, particularly in AD, with neurons regulating brain clearance through the glymphatic system (Jiang-Xie et al., 2024). In NDD treatment, Tsai's team found that multisensory gamma stimulation enhances CSF dynamics in AD mouse models, while vasoactive intestinal peptide interneurons facilitate glymphatic clearance (Murdock et al., 2024). This Research Topic comprises five following papers, categorized into Speech Analysis for Early Diagnosis of NDD, Neurobiological Markers in NDD, and Digital Therapy Progress of NDD.